Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease. It is also developing omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219
Debt
Debt-to-Equity Ratio-0.12
Current Ratio2.62
Quick Ratio2.62
Price-To-Earnings
Trailing P/E Ratio-20.58
Forward P/E Ratio-20.28
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.06 million
Price / Sales22.30
Cash FlowN/A
Price / CashN/A
Book Value($5.62) per share
Price / Book-7.29
Profitability
EPS (Most Recent Fiscal Year)($1.99)
Net Income$-47,670,000.00
Net Margins-53.89%
Return on EquityN/A
Return on Assets-28.97%
Miscellaneous
Employees93
Outstanding Shares26,160,000
Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions
What is Reata Pharmaceuticals' stock symbol?
Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."
How were Reata Pharmaceuticals' earnings last quarter?
Reata Pharmaceuticals Inc (NASDAQ:RETA) posted its quarterly earnings results on Tuesday, May, 8th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.61) by $0.76. The business earned $32.39 million during the quarter, compared to analysts' expectations of $10.21 million. View Reata Pharmaceuticals' Earnings History.
What price target have analysts set for RETA?
8 brokerages have issued 1 year price objectives for Reata Pharmaceuticals' stock. Their predictions range from $43.00 to $78.00. On average, they anticipate Reata Pharmaceuticals' share price to reach $54.7143 in the next year. View Analyst Ratings for Reata Pharmaceuticals.
What are Wall Street analysts saying about Reata Pharmaceuticals stock?
Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (5/9/2018)
- 2. Cowen Inc analysts commented, "RETA reported 3Q17 financials yesterday, noting that the three major programs." (11/14/2017)
Who are some of Reata Pharmaceuticals' key competitors?
Some companies that are related to Reata Pharmaceuticals include HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma A/S (ASND), Portola Pharmaceuticals (PTLA), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK) and Intercept Pharmaceuticals (ICPT).
Who are Reata Pharmaceuticals' key executives?
Reata Pharmaceuticals' management team includes the folowing people:
- Mr. J. Warren Huff, Chairman, CEO & Pres (Age 64)
- Dr. Colin J. Meyer, Chief Medical Officer & VP of Product Devel. (Age 39)
- Dr. Keith W. Ward, VP & Chief Devel. Officer (Age 48)
- Mr. Jason D. Wilson, CFO & VP of Strategy (Age 48)
- Ms. Elaine Castellanos, VP of Fin. & Accounting and Principal Accounting Officer
When did Reata Pharmaceuticals IPO?
(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.
Has Reata Pharmaceuticals been receiving favorable news coverage?
News headlines about RETA stock have been trending positive on Wednesday, according to Accern. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Reata Pharmaceuticals earned a media sentiment score of 0.44 on Accern's scale. They also assigned press coverage about the company an impact score of 47.78 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Reata Pharmaceuticals' major shareholders?
Reata Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.56%), Prosight Management LP (1.14%), JPMorgan Chase & Co. (0.65%), Northern Trust Corp (0.50%), King Luther Capital Management Corp (0.24%) and Landscape Capital Management L.L.C. (0.21%). Company insiders that own Reata Pharmaceuticals stock include A/S Novo, Abbvie Inc, Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr, Keith Wayne Ward and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.
Which major investors are selling Reata Pharmaceuticals stock?
Which major investors are buying Reata Pharmaceuticals stock?
RETA stock was bought by a variety of institutional investors in the last quarter, including Prosight Management LP, Landscape Capital Management L.L.C., Sofinnova Ventures Inc, Citadel Advisors LLC, Stifel Financial Corp, UBS Group AG, DekaBank Deutsche Girozentrale and King Luther Capital Management Corp. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.
How do I buy shares of Reata Pharmaceuticals?
Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Reata Pharmaceuticals' stock price today?
One share of RETA stock can currently be purchased for approximately $40.95.
How big of a company is Reata Pharmaceuticals?
Reata Pharmaceuticals has a market capitalization of $1.00 billion and generates $48.06 million in revenue each year. The company earns $-47,670,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Reata Pharmaceuticals employs 93 workers across the globe.
How can I contact Reata Pharmaceuticals?
Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]
MarketBeat Community Rating for Reata Pharmaceuticals (RETA)
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.
